Full Name
Mr. Thomas Tillett
Job Title
CEO and President
MBF Therapeutics
Speaker Bio
Thomas Tillett – Cofounder and CEO of MBF Therapeutics, an animal health company that is developing next generation gene based immunotherapies to treat cancer and infectious diseases in both companion animals and livestock. Tom is the founder and Executive Director of Sustained Acts, a Christian non-profit focusing on sustainable projects in Africa and serves on the Friends of Kijabe Hospital Board of Directors. Mr. Tillett was founder, and CEO of RHeoGene. As RheoGene CEO, he and his team created the RheoSwitch® Therapeutic System (RTS) that led to the first human clinical trial of a small molecule-induced gene regulation system. In 2007, he successfully completed the merger of RheoGene Inc. with Intrexon Corporation who has continued the development of RTS through a various clinical trials for cancer and other important therapeutic indications. In April, 2019 the FDA announced that the RheoSwitch Therapeutic System for glioma blastoma was approved for Fast Track designation.
Thomas Tillett